加科思(01167.HK)治疗肿瘤突变药物于中国完成首例患者给药

阿斯达克财经
25 Nov 2024

加科思-B(01167.HK) 公布,其自主研发的泛KRAS抑制剂“JAB-23E73”在中国完成I/IIa期临床试验首例患者给药。
加科思表示,KRAS广泛存在于多种肿瘤突变,约23%至25%的癌症患者带有KRAS突变,全球每年新增约270万带有KRAS相关突变的肿瘤患者有望从泛KRAS抑制剂中获益。至于“JAB-23E73”可同时抑制KRAS的活性及非活性状态的KRAS,并对HRAS、NRAS无明显抑制。作为口服KRAS抑制剂,“JAB-23E73”的临床前资料展现了良好的药代动力学特性。(js/w)

(港股报价延迟最少十五分钟。)

AASTOCKS新闻

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10